Patnaik Highlights Evolution Toward Immunotherapy in Prostate Cancer
The role of immunotherapy may have had a slower uptick in patients with prostate cancer compared with other tumor types, but progress is being made, explains Akash Patnaik, MD, PhD, an assistant professor of Medicine at the University of Chicago Medicine. Aside from the immuno-based agent sipuleucel-T (Provenge), Patnaik discussed the status with immunotherapy and…
